BUFFALO, N.Y., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced the receipt of the End-of-Phase II meeting minutes (the “Minutes”) and an Advice Letter providing further clarification on the remaining clinical study protocols for the development of Entolimod™ (CBLB502) as a radiation countermeasure from the U.S. Food and Drug Administration (the “FDA”).
